- Home
- TROX vs REPL Comparison
TROX vs REPL Comparison
Compare TROX & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TROX
- REPL
- Stock Information
- Founded
- TROX 2018
- REPL 2015
- Country
- TROX United States
- REPL United States
- Employees
- TROX N/A
- REPL N/A
- Industry
- TROX Major Chemicals
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- TROX Industrials
- REPL Health Care
- Exchange
- TROX Nasdaq
- REPL Nasdaq
- Market Cap
- TROX 653.1M
- REPL 547.0M
- IPO Year
- TROX 2005
- REPL 2018
- Fundamental
- Price
- TROX $4.85
- REPL $5.73
- Analyst Decision
- TROX Buy
- REPL Hold
- Analyst Count
- TROX 8
- REPL 9
- Target Price
- TROX $5.51
- REPL $7.00
- AVG Volume (30 Days)
- TROX 3.6M
- REPL 2.3M
- Earning Date
- TROX 10-23-2025
- REPL 11-11-2025
- Dividend Yield
- TROX 4.13%
- REPL N/A
- EPS Growth
- TROX N/A
- REPL N/A
- EPS
- TROX N/A
- REPL N/A
- Revenue
- TROX $2,949,000,000.00
- REPL N/A
- Revenue This Year
- TROX N/A
- REPL N/A
- Revenue Next Year
- TROX $4.56
- REPL $408.25
- P/E Ratio
- TROX N/A
- REPL N/A
- Revenue Growth
- TROX 0.24
- REPL N/A
- 52 Week Low
- TROX $2.95
- REPL $2.68
- 52 Week High
- TROX $15.07
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- TROX 61.05
- REPL 47.00
- Support Level
- TROX $3.97
- REPL $5.74
- Resistance Level
- TROX $4.65
- REPL $6.15
- Average True Range (ATR)
- TROX 0.25
- REPL 0.35
- MACD
- TROX 0.13
- REPL 0.11
- Stochastic Oscillator
- TROX 81.78
- REPL 34.19
About TROX Tronox Holdings plc (UK)
Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.